Targovax ASA: Invitation to presentation of Targovax’s third quarter 2021 results, Thursday 4 November

Oslo, Norway, 27 October 2021 – Targovax ASA (OSE: TRVX) will announce its third quarter 2021 results on Thursday 4 November 2021. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 am CET.

The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 am CET.

Presentation

There will be a virtual presentation of the results with a live webcast 4 November at 10.00 am CET. You can join the webcast here. It will be possible to ask questions during the presentation.

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 906 56 525
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The company’s product candidates are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both in monotherapy and in multiple combinations, the next development steps for ONCOS-102 will be to further improve responses in melanoma patients resistant to or poorly responsive to current standard of care.